GNAZ Slows Lung Cancer Growth by Triggering KIF11 Destruction and Boosts Osimertinib Response

A protein called GNAZ, long overlooked in lung cancer research, appears to act as a brake on lung adenocarcinoma, according to a new study published in Cell & Bioscience. The work, led by Shuning Kong, Feifei Mao and colleagues with senior author Jiang Fan, combines analysis of large public datasets with experiments in clinical specimens, cultured lung cancer cells and mouse models, and points to a previously underappreciated molecular pathway that also influences how tumors respond to a widely used targeted drug.

The researchers began by examining GNAZ expression in data from The Cancer Genome Atlas and GEO repositories, then validated their findings in clinical samples. Across these analyses, GNAZ, a heterotrimeric G-protein alpha subunit that had remained poorly characterized in lung cancer, was consistently reduced in lung adenocarcinoma tissue compared with healthy tissue. Notably, patients whose tumors showed higher GNAZ levels tended to have longer overall survival, an association that motivated the team to probe the protein’s function directly.

Functional experiments in the laboratory supported a tumor-suppressive role. When the researchers forced lung adenocarcinoma cells to overproduce GNAZ, the cells proliferated more slowly and showed reduced migration and invasion. In xenograft models, tumors carrying elevated GNAZ grew less aggressively. Conversely, depleting GNAZ from the cells produced the opposite effects, accelerating proliferation, motility and tumor growth. Together, these gain- and loss-of-function results position GNAZ as a factor that constrains multiple malignant behaviors of lung adenocarcinoma cells.

To understand how GNAZ exerts these effects, the team turned to transcriptomic and proteomic profiling, which identified KIF11, a kinesin motor protein involved in cell division, as a functionally relevant downstream effector. The mechanistic experiments that followed were extensive. Co-immunoprecipitation showed that GNAZ physically associates with KIF11. Cycloheximide-chase assays demonstrated that KIF11 protein degrades more rapidly in the presence of GNAZ, and MG132 rescue experiments confirmed that this degradation proceeds through the proteasome, the cellular machinery that dismantles ubiquitin-tagged proteins.

The degradation pathway itself proved to depend on HUWE1, an E3 ubiquitin ligase. Ubiquitination assays showed that GNAZ facilitates HUWE1-dependent attachment of ubiquitin to KIF11, and experiments in which HUWE1 was depleted supported this dependency. In practical terms, GNAZ appears to act as an adaptor or facilitator that hands KIF11 over to HUWE1 for destruction, thereby lowering the amount of this motor protein available to the cancer cell.

Downstream of KIF11 loss, the researchers observed reduced Wnt/beta-catenin signaling and an attenuation of mesenchymal features, the cellular characteristics associated with invasiveness and metastatic potential. This chain of events, from GNAZ through HUWE1-mediated KIF11 ubiquitination to dampened Wnt signaling and a less aggressive cell state, offers a coherent mechanistic account of how a G-protein subunit can influence tumor progression.

The study also connected this pathway to therapy. Osimertinib is a standard targeted treatment for EGFR-mutant lung adenocarcinoma, yet substantial variation in treatment response remains a clinical problem. In both cell-based and in vivo lung adenocarcinoma models, GNAZ increased the antitumor effect of osimertinib. Importantly, when the researchers restored KIF11 in these models, the enhancement was partially counteracted, indicating that KIF11 degradation is a meaningful contributor to the drug-sensitizing effect of GNAZ rather than a bystander observation.

Looking upstream, the team identified KLF5 as a candidate negative regulator of GNAZ transcription, suggesting a potential mechanism by which lung cancer cells might suppress this tumor-inhibitory protein. The authors are careful to note, however, that direct regulation of GNAZ by KLF5 remains to be established, so this part of the circuit is best regarded as a hypothesis for future testing rather than a settled finding.

The study’s own summary frames the work with appropriate caution. The findings establish a GNAZ-HUWE1/KIF11 regulatory axis that limits lung adenocarcinoma progression and modulates osimertinib responsiveness in the models tested, providing a mechanistic basis for further investigation of this pathway in EGFR-targeted therapy. Whether the same pathway contributes to acquired osimertinib resistance remains an open question that the authors say will need to be addressed in clinically relevant resistant models.

For patients and clinicians, the immediate takeaway is not a new treatment but a new lead. The work is early-stage and preclinical, resting on dataset analyses, cell culture experiments and animal models rather than clinical trials, and the article was shared early as a peer-reviewed accepted manuscript subject to further edits. Even so, by linking a poorly understood G-protein to KIF11 stability, Wnt signaling and osimertinib response, the study adds a candidate node to the molecular map of lung adenocarcinoma and suggests that measuring or manipulating this axis could eventually help explain why some patients with EGFR-mutant disease respond better to osimertinib than others.

Subject of Research: The role of the GNAZ-HUWE1/KIF11 pathway in lung adenocarcinoma progression and osimertinib response

Article Title: GNAZ suppresses lung adenocarcinoma progression through HUWE1-mediated KIF11 ubiquitination and modulates the response to osimertinib

Article References: Kong, S., Mao, F., Zhang, Y., Ye, D., Huang, W., Wu, L., Liu, H., & Fan, J. (2026). GNAZ suppresses lung adenocarcinoma progression through HUWE1-mediated KIF11 ubiquitination and modulates the response to osimertinib. Cell & Bioscience. https://doi.org/10.1186/s13578-026-01665-1

Image Credits: AI Generated

DOI: 10.1186/s13578-026-01665-1

Keywords: GNAZ, lung adenocarcinoma, KIF11, HUWE1, ubiquitination, osimertinib, EGFR-mutant lung cancer, Wnt/beta-catenin signaling, KLF5, tumor suppressor, proteasomal degradation, Cell & Bioscience